-
Apellis Pharmaceuticals NASDAQ:APLS Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that is committed to leveraging courageous science, creativity, and compassion to deliver life-changing therapies. Leaders in targeted C3 therapies, the company aims to develop transformative therapies for a broad range of debilitating diseases that are driven by excessive activation of the complement cascade, including those within hematology, ophthalmology, nephrology, and neurology.
Location: 100 Fifth Avenue, Massachusetts, 02451, United States | Website: apellis.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
3.581B
Cash
403.7M
Avg Qtr Burn
-51.28M
Short % of Float
24.56%
Insider Ownership
13.98%
Institutional Own.
93.48%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
SYFOVRE™(Intravitreal pegcetacoplan) Details Age-related macular degeneration, Geographic atrophy | Approved Quarterly sales | |
Empaveli (systemic pegcetacoplan) (APL-2) Details Paroxysmal nocturnal hemoglobinuria | Approved Quarterly sales | |
Systemic pegcetacoplan (APL-2) Details Immune complex membranoproliferative glomerulonephritis, C3 Glomerulopathy | sNDA Submission | |
Systemic pegcetacoplan (APL-2) Details Hematopoietic stem cell transplantation thrombotic microangiopathies | Phase 2 Data readout | |
Systemic pegcetacoplan (APL-2) Details Immune complex membranoproliferative glomerulonephritis, C3 Glomerulopathy | Phase 2 Update | |
APL-3007 (small interfering RNA silencing C3) Details Autoimmune disease, Inflammatory disease | Phase 1 Data readout | |
Systemic pegcetacoplan (APL-2) Details Amyotrophic lateral sclerosis | Failed Discontinued | |
Systemic pegcetacoplan (APL-2) Details Cold agglutinin disease | Failed Discontinued | |
Intravenous APL-9 Details ARDS (Acute respiratory distress syndrome), TMA (Thrombotic microangiopathies) | Failed Discontinued |